Evidence map›Paper›PMID 25919029›Full record

ArticlePLoS medicine2015

Defining the in vivo phenotype of artemisinin-resistant falciparum malaria: a modelling approach.

Lisa J White, Jennifer A Flegg, Aung Pyae Phyo, Ja Hser Wiladpai-ngern, Delia Bethell, Christopher Plowe, Tim Anderson, Standwell Nkhoma, Shalini Nair, Rupam Tripura and 10 more

Open access · goldAbstract read
In one paragraph

Article in PLoS medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
6.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Efficacy of Artemether-Lumefantrine for UncomplicatedThe American journal of tropical medicine and hygiene · 2018
    Trial
  3. Article
  4. Review
  5. Article
  6. Resistance to Antimalarial Monotherapy Is Cyclic.Journal of clinical medicine · 2022
    Article
  7. Plasmodium falciparum resistance to ACTs: Emergence, mechanisms, and outlook.International journal for parasitology. Drugs and drug resistance · 2021
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 4 countries.

Lisa J WhiteCentre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Jennifer A FleggWorldwide Antimalarial Resistance Network, Oxford University, Oxford, United Kingdom.
Aung Pyae PhyoCentre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
Ja Hser Wiladpai-ngernShoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
Delia BethellHoward Hughes Medical Institute/Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
Christopher PloweDepartment of Genetics, Texas Biomedical Research Institute, San Antonio, Texas, United States of America.
Tim AndersonNational Malaria Center, Ministry of Health, Phnom Penh, Cambodia.
Standwell NkhomaNational Malaria Center, Ministry of Health, Phnom Penh, Cambodia.
Shalini NairNational Malaria Center, Ministry of Health, Phnom Penh, Cambodia.
Rupam TripuraMahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Kasia StepniewskaWorldwide Antimalarial Resistance Network, Oxford University, Oxford, United Kingdom.
Wirichada Pan-NgumMahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Kamolrat SilamutMahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Ben S CooperCentre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Yoel LubellCentre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Elizabeth A AshleyCentre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Chea NguonNational Malaria Center, Ministry of Health, Phnom Penh, Cambodia.
François NostenCentre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
Nicholas J WhiteCentre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Arjen M DondorpCentre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Mahidol University · THUniversity of Oxford · GBMinistry of Health · KHMahidol Oxford Tropical Medicine Research Unit · THArmed Forces Research Institute of Medical Science · THTexas Biomedical Research Institute · USUniversity of Maryland, Baltimore · US

Funding

Mapping Drug Resistance Genes in Plasmodium falciparumR37AI048071 · NIAID · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI ANDERSON, TIM J · 2012 to 2021
$7.9M
Howard Hughes Medical InstituteNIAID NIH HHS R37 AI048071Wellcome Trust 077166/Z/05/ZWellcome Trust 093956
6 · The paper itself

Abstract

backgroundArtemisinin-resistant falciparum malaria has emerged in Southeast Asia, posing a major threat to malaria control. It is characterised by delayed asexual-stage parasite clearance, which is the reference comparator for the molecular marker 'Kelch 13' and in vitro sensitivity tests. However, current cut-off values denoting slow clearance based on the proportion of individuals remaining parasitaemic on the third day of treatment ('day-3'), or on peripheral blood parasite half-life, are not well supported. We here explore the parasite clearance distributions in an area of artemisinin resistance with the aim refining the in vivo phenotypic definitions. METHODS AND

findingsData from 1,518 patients on the Thai-Myanmar and Thai-Cambodian borders with parasite half-life assessments after artesunate treatment were analysed. Half-lives followed a bimodal distribution. A statistical approach was developed to infer the characteristics of the component distributions and their relative contribution to the composite mixture. A model representing two parasite subpopulations with geometric mean (IQR) parasite half-lives of 3.0 (2.4-3.9) hours and 6.50 (5.7-7.4) hours was consistent with the data. For individual patients, the parasite half-life provided a predicted likelihood of an artemisinin-resistant infection which depends on the population prevalence of resistance in that area. Consequently, a half-life where the probability is 0.5 varied between 3.5 and 5.5 hours. Using this model, the current 'day-3' cut-off value of 10% predicts the potential presence of artemisinin-resistant infections in most but not all scenarios. These findings are relevant to the low-transmission setting of Southeast Asia. Generalisation to a high transmission setting as in regions of Sub-Saharan Africa will need additional evaluation.

conclusionsCharacterisation of overlapping distributions of parasite half-lives provides quantitative insight into the relationship between parasite clearance and artemisinin resistance, as well as the predictive value of the 10% cut-off in 'day-3' parasitaemia. The findings are important for the interpretation of in vitro sensitivity tests and molecular markers for artemisinin resistance and for contextualising the 'day 3' threshold to account for initial parasitaemia and sample size.

Indexed as

Drug ResistancePhenotypeAntimalarialsArtemisininsArtesunateCambodiaHumansLife Cycle StagesMalaria, FalciparumMyanmarParasite LoadParasitemiaPhylogenyPlasmodium falciparumReference ValuesThailandAntimalarialsartemisininArtemisininsArtesunate

Identifiers

PMID25919029
PMCPMC4412633
OpenAlexW2094294963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.